Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors

1 Dec 2020

Abstract excerpt

Epigenetic factors play important roles in tumor immunology. Histone-lysine N-methyltransferase 2 (KMT2) family genes exert histone H3 methylation, but its role in immunotherapy remains unclear. Our study is the first to investigate the correlation between KMT2 gene mutations and the clinical benefit of immune checkpoint inhibitors (ICI) treatment. We firstly collected a primary ICI-treated cohort (n = 546) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33298164
DOI: 10.1186/s40364-020-00241-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsPMID 33298164Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

KMT2C is Potential Prognostic Biomarker and its Immune Regulating Roles in Pan-Cancer: A Comprehensive AnalysisSemantic proximity Read ↗

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancersSemantic proximity Read ↗

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.Semantic proximity Read ↗

Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.Semantic proximity Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer.Semantic proximity Read ↗

A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in CancerSemantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read ↗

Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.